Italy reviews GLP-1 obesity drugs amid cost and access concerns

GLP‑1 receptor agonists such as semaglutide and tirzepatide are reshaping treatment for diabetes and obesity in Italy. Recent regulatory approvals have expanded prescriptions, and many patients now seek these medicines primarily for weight loss, creating queues and prompting calls for clearer prescribing guidelines. Clinical data show significant weight reduction, better glycaemic control and possible cardiovascular benefits, though side‑effects like digestive issues are common and stopping therapy often leads to rapid weight regain.

A new analysis highlights the financial strain of widespread GLP‑1 use on Italy’s public health system. While the drugs may lower long‑term complications and associated costs for patients with diabetes, the high upfront price could exceed budget limits when applied to the broader obese population. Insurance coverage and reimbursement policies are therefore under debate, as sustained adherence remains uncertain and the overall cost‑benefit balance is still being evaluated.